Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 523

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 523
---
                       | $ |    434 | ​ | ​ | ​ | ​    | $ |  5,048 | ​ | ​ |
| Supplemental disclosure of cash flow information                             | ​ | ​ | ​                       | ​ |      ​ | ​ | ​ | ​ | ​    | ​ |      ​ | ​ | ​ |
| Cash paid for interest                                                       | ​ | ​ | ​                       | $ |      — | ​ | ​ | ​ | ​    | $ |    503 | ​ | ​ |
| Cash paid for income taxes                                                   | ​ | ​ | ​                       | $ |      — | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |
| Supplemental disclosure of non-cash financing and investing activities:      | ​ | ​ | ​                       | ​ |      ​ | ​ | ​ | ​ | ​    | ​ |      ​ | ​ | ​ |
| Cancellation of member units related to Metavagen license termination        | ​ | ​ | ​                       | $ |    239 | ​ | ​ | ​ | ​    | ​ |      ​ | ​ | ​ |
| Issuance of Class A member units in exchange for CD-47 License Agreement     | ​ | ​ | ​                       | $ |    786 | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |
| Issuance of Class A member units in exchange for Metavagen License Agreement | ​ | ​ | ​                       | ​ |      ​ | ​ | ​ | ​ | ​    | $ |    400 | ​ | ​ |

The accompanying notes are an integral part of these financial statements. F-74

TABLE OF CONTENTS

#### LIMINATUS PHARMA, LLC

### NOTES TO FINANCIAL STATEMENTSDECEMBER 31, 2023 AND 2022

### Note 1. Organization and Description of Business Operations
Liminatus Pharma, LLC (“Liminatus” or the “Company”) was formed by issuing member units to Consonatus, Inc. (the “Initial Member”), which is controlled by Chris Kim, the Chief Executive Officer (“CEO”) of the Company, on April 12, 2018 under the laws of Delaware. Liminatus is a clinical stage life sciences and pre-revenue company developing Guanylyl Cyclase C (“GCC”) chimeric antigen receptor (“CAR”)-T products and a GCC cancer vaccine, known as